Inhibition of hdac activity by itf2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis

Molecular Medicine

Volumn 17, Issue 5-6, 2011, Pages 391-396

  Joosten, Leo Ab ^a   Leoni, Flavio ^b   Meghji, Sajeda ^c   Mascagni, Paolo ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Italfarmaco SpA   (Italy)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; COLLAGEN TYPE 2; DEXAMETHASONE; GAMMA INTERFERON; GIVINOSTAT; INTERLEUKIN 12; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; LEFLUNOMIDE; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; ROMIDEPSIN; TRICHOSTATIN A; TUMOR NECROSIS FACTOR ALPHA;

ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; BONE ATROPHY; BONE DESTRUCTION; CALCIUM TRANSPORT; CARTILAGE CELL; CARTILAGE DEGENERATION; CELL TRANSPORT; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG TOLERABILITY; ENZYME INHIBITION; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; JOINT SWELLING; NONHUMAN; OSTEOLYSIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEOGLYCAN SYNTHESIS; SYNOVIUM;

ANIMALS; ARTHRITIS, EXPERIMENTAL; BONE DISEASES; BONE RESORPTION; CARTILAGE DISEASES; COLLAGEN; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; INTERLEUKIN-1BETA; JOINTS; MICE; MICE, INBRED C57BL; RATS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79957958931     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2011.00058     Document Type: Article

References (41)

1. Khan N, et al. (2008) Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409:581-9.
2. Gerstner T, Bell N, Konig S. (2008) Oral valproic acid for epilepsy-long-term experience in therapy and side effects. Expert. Opin. Pharmacother. 9:285-92.
3. Ren M, Leng Y, Jeong M, Leeds PR, Chuang DM. (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89:1358-67.
4. Marks PA, et al. (2001) Histone deacetylases and cancer: causes and therapies. Nature Rev. Cancer. 1:194-202.
5. Vojinovic J, et al. (2011) Safety and efficacy of an oral histone deacetylase inhibitor in systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 63:1452-8.
6. O'Connor OA, et al. (2006) Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoy-lanilide hydroxamic acid in patients with advanced hematologic malignancies. J. Clin. Oncol. 24:166-73.
7. Richon VM, Zhou X, Rifkind RA, Marks PA. (2001) Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (saha) for the treatment of cancers. Blood Cells Mol. Dis. 27:260-4.
8. Park JH, et al. (2004) Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin. Cancer Res. 10:5271-81.
9. Leoni F, et al. (2002) The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc. Natl. Acad. Sci. U.S.A. 99:2995-3000.
10. Matalon S, et al. (2010) The histone deacetylase in hibitor ITF2357 decreases surface CXCR4 and CCR5 expression on CD4+ T-cells and monocytes and is superior to valproic acid for latent HIV-1 expression in vitro. J. Acquir. Immune Defic. Syndr. 54:1-9.
11. Reddy P, et al. (2004) Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc. Natl. Acad. Sci. U.S.A. 101:3921-6.
12. Reilly CM, et al. (2004) Modulation of renal disease in MRL/lpr mice by suberoylanilide hy-droxamic acid. J. Immunol. 173:4171-8.
13. Glauben R, et al. (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J. Immunol. 176:5015-22.
14. Leoni F, et al. (2005) The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol. Med. 11:1-15.
15. Leng C, et al. (2006) Reduction of graft-versus-host disease by histone deacetylase inhibitor suberony-lanilide hydroxamic acid is associated with modulation of inflammatory cytokine milieu and involves inhibition of STAT1. Exp. Hematol. 34:776-87.
16. Shein NA, et al. (2009) Histone deacetylase inhibitor ITF2357 is neuroprotective, improves functional recovery, and induces glial apoptosis following experimental traumatic brain injury. FASEB J. 23:4266-75.
17. Glauben R, et al. (2008) Histone deacetylases: novel targets for prevention of colitis-associated cancer in mice. Gut. 57:613-22.
18. Kawabata T, et al. (2010) Increased activity and expression of histone deacetylase 1 in relation to tumor necrosis factor-alpha in synovial tissue of rheumatoid arthritis. Arthritis Res. Ther. 12:R133.
19. Grabiec AM, et al. (2010) Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue. J. Immunol. 184:2718-28.
20. Rosato RR, et al. (2003) Simultaneous activation of the intrinsic and extrinsic pathways by histone deacetylase (HDAC) inhibitors and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) synergistically induces mitochondrial damage and apoptosis in human leukemia cells. Mol. Cancer Ther. 2:1273-84.
21. Choo QY, et al. (2010) Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaBp65 nuclear accumulation in human rheumatoid arthritis synovial fibro -blastic E11 cells. Rheumatology. 49:1447-60.
22. Nasu Y, et al. (2008) Trichostatin A, a histone deacetylase inhibitor, suppresses synovial inflammation and subsequent cartilage destruction in a collagen antibody-induced arthritis mouse model. Osteoarthritis Cartilage. 16:723-32.
23. Nishida K, et al. (2004) Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 50:3365-76.
24. Dinarello CA, Fossati G, Mascagni P. (2011) Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol. Med. 17:333-352.
25. Saouaf SJ, et al. (2009). Deacetylase inhibition increases regulatory T cell function and decreases incidence and severity of collagen-induced arthritis. Exp. Mol. Pathol. 87:99-104.
26. Saklatvala J, Dingle JT. (1980) Identification of catabolin, a protein fro synovium which induces degradation of cartilage in organ culture. Biochem. Biophys. Res. Commun. 96:1225-31.
27. Abdollahi-Roodsaz S, et al. (2009) Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation. Am. J. Pathol. 175:2004-13.
28. Kuiper S, et al. (1998) Different roles of tumour necrosis factor alpha and interleukin 1 in murine streptococcal cell wall arthritis. Cytokine. 10:690-702.
29. Joosten LA, et al. (1999) IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J. Immunol. 163:5049-55.
30. Joosten LA, et al. (2008) T cell dependence of chronic destructive murine arthritis induced by repeated local activation of Toll-like receptor-driven pathways: crucial role of both interleukin-1beta and interleukin-17. Arthritis Rheum. 58:98-108.
31. Joosten LA, et al. (2003) Toll-like receptor 2 pathway drives streptococcal cell wall-induced joint inflammation: critical role of myeloid differentiation factor 88. J. Immunol. 171:6145-53.
32. Joosten LA, et al. (2008) Differential function of the NACHT-LRR (NLR) members Nod1 and Nod2 in arthritis. Proc. Natl. Acad. Sci. U.S.A. 105:9017-22.
33. Lin HS, et al. (2007) Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br. J. Pharmacol. 150:862-72.
34. Zwerina J, et al. (2007) TNF-induced structural joint damage is mediated by IL-1. Proc. Natl. Acad. Sci. U.S.A. 104:11742-7.
35. Polzer K, et al. (2010) Interleukin-1 is essential for systemic inflammatory bone loss. Ann. Rheum. Dis. 69:284-90.
36. Gowen M, Mundy GR. (1986) Actions of recombi-nant interleukin 1, interleukin 2, and interferon-gamma on bone resorption in vitro. J. Immunol. 136:2478-82.
37. Kim HN, et al. (2009) Trichostatin A inhibits os-teoclastogenesis and bone resorption by suppressing the induction of c-Fos by RANKL. Eur. J. Pharmacol. 623:22-9.
38. Nakamura T, et al. (2005) Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J. Immunol. 175:5809-16.
39. Young DA, et al. (2005) Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorp-tion. Arthritis Res. Ther. 7:R503-12.
40. Wang X, Song Y, Jacobi JL, Tuan RS. (2009) Inhibition of histone deacetylases antagonized FGF2 and IL-1beta effects on MMP expression in human articular chondrocytes. Growth Factors. 27:40-9.
41. Higashiyama R, et al. (2010) Correlation between MMP-13 and HDAC7 expression in human knee osteoarthritis. Mod. Rheumatol. 20:11-7.